Global Genomic and RNA Profiles for Novel Risk Stratification of Neuroblastoma

Overview

Journal Cancer Sci

Specialty Oncology

Date 2010 Aug 25

PMID 20731666

Citations 16

Authors

Miki Ohira

Akira Nakagawara

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is one of the most common solid tumors in children. Its clinical behavior ranges widely from spontaneous regression to life-threatening aggressive growth. The molecular etiology of neuroblastoma is still enigmatic and the overall cure rate of advanced disease is still very poor. Recent microarray-based technology provided us with important information such as comprehensive genomic alterations and gene expression profiles to help us understand the molecular characteristics of each tumor in detail. Several retrospective studies have revealed that these signatures are strongly correlated with patient prognoses and led to the construction of new risk stratification systems, some of which are considered for evaluation in upcoming clinical studies in a prospective way. Large-scale analyses using a variety of genetic tools also discovered a major familial neuroblastoma predisposition gene ALK, as well as new candidate susceptibility genes at 6q22 and 2q35 for sporadic neuroblastoma. Of note, ALK is mutated in 6-9% of sporadic cases, and is either amplified or constitutively activated through mutations mainly within the kinase domain, promoting the possibility of new therapeutic strategies using ALK inhibitors. Additional candidates for outcome predictors such as the methylation phenotype of tumor DNA and expression profiles of microRNA have also been proposed. Such variety of information will help us understand the heterogeneity of neuroblastoma biology and further, the combined use of these signatures will be beneficial in predicting prognosis with high accuracy, as well as choosing a suitable therapy for the individual patient.

Citing Articles

Chromosome instability in neuroblastoma: A pathway to aggressive disease.

Paolini L, Hussain S, Galardy P Front Oncol. 2022; 12:988972.

PMID: 36338721 PMC: 9633097. DOI: 10.3389/fonc.2022.988972.

Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children's Cancer Group Neuroblastoma Committee (JCCG-JNBSG).

Ohira M, Nakamura Y, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K Biomolecules. 2022; 12(1).

PMID: 35053166 PMC: 8774029. DOI: 10.3390/biom12010018.

Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound.

Luczkowska K, Sokolowska K, Taryma-Lesniak O, Pastuszak K, Supernat A, Bybjerg-Grauholm J Sci Rep. 2021; 11(1):9846.

PMID: 33972578 PMC: 8110815. DOI: 10.1038/s41598-021-89128-0.

Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T Int J Clin Oncol. 2018; 23(5):965-973.

PMID: 29700636 DOI: 10.1007/s10147-018-1281-8.

Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway.

Li Y, Ohira M, Zhou Y, Xiong T, Luo W, Yang C Oncotarget. 2017; 8(34):56684-56697.

PMID: 28915622 PMC: 5593593. DOI: 10.18632/oncotarget.18079.

References

Chen Y, Stallings R . Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007; 67(3):976-83. DOI: 10.1158/0008-5472.CAN-06-3667. View

Amiel J, Laudier B, Attie-Bitach T, Trang H, De Pontual L, Gener B . Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat Genet. 2003; 33(4):459-61. DOI: 10.1038/ng1130. View

Fontana L, Fiori M, Albini S, Cifaldi L, Giovinazzi S, Forloni M . Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One. 2008; 3(5):e2236. PMC: 2375057. DOI: 10.1371/journal.pone.0002236. View

Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A . Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene. 2002; 21(38):5823-34. DOI: 10.1038/sj.onc.1205735. View

Hamano S, Ohira M, Isogai E, Nakada K, Nakagawara A . Identification of novel human neuronal leucine-rich repeat (hNLRR) family genes and inverse association of expression of Nbla10449/hNLRR-1 and Nbla10677/hNLRR-3 with the prognosis of primary neuroblastomas. Int J Oncol. 2004; 24(6):1457-66. View

Mosse Y, Laudenslager M, Khazi D, Carlisle A, Winter C, Rappaport E . Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet. 2004; 75(4):727-30. PMC: 1182065. DOI: 10.1086/424530. View

Nakagawara A, Azar C, Scavarda N, Brodeur G . Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol. 1994; 14(1):759-67. PMC: 358424. DOI: 10.1128/mcb.14.1.759-767.1994. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Godfried M, Veenstra M, Sluis P, Boon K, v Asperen R, Hermus M . The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene. 2002; 21(13):2097-101. DOI: 10.1038/sj.onc.1205259. View

10.

Schulte J, Horn S, Otto T, Samans B, Heukamp L, Eilers U . MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer. 2007; 122(3):699-704. DOI: 10.1002/ijc.23153. View

11.

Maris J . The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005; 17(1):7-13. DOI: 10.1097/01.mop.0000150631.60571.89. View

12.

Bown N, Cotterill S, Lastowska M, ONeill S, Pearson A, Plantaz D . Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999; 340(25):1954-61. DOI: 10.1056/NEJM199906243402504. View

13.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

14.

Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J . Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009; 10(7):663-71. PMC: 3045079. DOI: 10.1016/S1470-2045(09)70154-8. View

15.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

16.

Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D . Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009; 27(7):1026-33. DOI: 10.1200/JCO.2008.16.0630. View

17.

Li R, Morris S . Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2007; 28(3):372-412. DOI: 10.1002/med.20109. View

18.

Nakagawara A, Scavarda N, Azar C, Cantor A, Brodeur G . Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993; 328(12):847-54. DOI: 10.1056/NEJM199303253281205. View

19.

Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q . Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004; 64(19):6883-91. PMC: 1298184. DOI: 10.1158/0008-5472.CAN-04-0695. View

20.

Look A, Hayes F, Nitschke R, MCWILLIAMS N, Green A . Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984; 311(4):231-5. DOI: 10.1056/NEJM198407263110405. View